PRMT5 and breast carcinoma: Importantly, treatment with GSK591, a selective PRMT5 inhibitor, effectively inhibits the circMMP2(6,7)/β-catenin/PRMT5 complex-induced bone metastasis, highlighting a potential therapeutic target for managing breast cancer bone metastasis [123].